AlphaYou
Overview
Key stats
Fundamentals Sep 9- Open
- $146.05
- 52-wk high
- $160.81
- High
- $151.19
- 52-wk low
- $57.52
- Low
- $144.48
- Prev close
- $145.94
- Mkt cap
- $9.44B
- P/E
- 140.3x
- Volume
- 530.5K
- Fwd P/E
- 36.9x
- Beta
- 1.79
- P/S
- 33.5x
- P/B
- 11.2x
- Profit margin
- +29.4%
- Op margin
- +74.4%
- ROE
- +11.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
Earnings
Earnings came in 8.5% above what analysts expected.
Earnings per share
$2.11 expected
What the street expects next
EPS expected
$0.13 to $3.71
Revenue expected
11 analysts
Last 30 days
Split both ways
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $4.7M | $7.4M | $56.4M | $213.5M |
| Cost of what it sold | — | $376.0K | $407.0K | — |
| Gross profit | $4.7M | $7.4M | $56.0M | $213.5M |
| What it spent | ||||
| Research and development | $40.0M | $46.4M | $46.7M | $42.1M |
| Sales and admin | $11.1M | $11.4M | $13.3M | $12.6M |
| Total operating expenses | $51.1M | $57.8M | $59.6M | $54.7M |
| What was left | ||||
| Operating profit | -$46.4M | -$50.4M | -$3.6M | $158.8M |
| Profit before tax | -$39.3M | -$43.7M | $2.3M | $165.1M |
| Tax | — | $666.0K | -$1.5M | $2.3M |
| Net profit | -$39.3M | -$44.4M | $3.8M | $162.8M |
| EBITDA | -$39.0M | -$43.3M | $2.7M | $165.1M |
Technicals
Price structure
This stock's price action is mixed.
Trend
Mixed
45 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
BullishSep 8Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
BullishSep 7Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
Leans bullishSep 2Protagonist Therapeutics (PTGX) Could Be 63% Below Fair Value After Investor Update Call
NeutralSep 1Wolfe Research reiterates Protagonist Therapeutics stock rating at outperform
BullishSep 1132,351 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Legal & General Group Plc
Leans bullishAug 31Citigroup Raises Protagonist Therapeutics Price Target to $182 From $175, Buy Rating Kept
BullishAug 31Wellington Management Group LLP Sells 182,863 Shares of Protagonist Therapeutics, Inc. $PTGX
Leans bullishAug 31
Macro
11 macro signals shaping PTGX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results